Previous 10 | Next 10 |
Dosing of first patients follows recent presentation of positive preliminary data from Phase 1a dose escalation portion of ADVANCED-1 trial Company advancing NMIBC clinical development program, with Phase 1b/2 trial in BCG-unresponsive CIS patients and in BCG-naïve and BCG-expose...
2023-05-04 13:36:07 ET Protara Therapeutics press release ( NASDAQ: TARA ): Q1 GAAP EPS of -$0.80. Continue to expect cash, cash equivalents and investments of $90M as of March 31, 2023 to fund operations into 2025 For further details see: Protara Therapeutics GA...
Favorable tolerability and anti-tumor activity observed in NMIBC patients treated with TARA-002 in ADVANCED-1 trial Company plans to initiate ADVANCED-2 trial in BCG-naïve CIS patients and BCG-unresponsive CIS patients in 2H23 Regulatory clearance received from FDA to...
2023-05-02 08:46:59 ET Protara Therapeutics ( NASDAQ: TARA ) received clearance from the U.S. Food and Drug Administration (FDA) to start a trial of TARA-002 to treat children with a rare disease called lymphatic malformations (LMs). LMs are non-cancerous vascular le...
STARBORN-1 trial leverages data from TARA-002 predecessor therapy OK-432, which is approved and has treated thousands of pediatric patients with Lymphatic Malformations in Japan and Taiwan as well as over 500 patients in a compassionate use study completed in the U.S. TARA-002 previously ...
2023-04-28 08:59:54 ET Protara Therapeutics ( NASDAQ: TARA ) has reported encouraging preliminary results from a Phase 1a dose-escalation trial of its investigational cell-based therapy, TARA-002, aimed at treating high-grade non-muscle invasive bladder cancer (NMIBC) patients. ...
Favorable tolerability observed in patients with NMIBC treated with TARA-002 in ADVANCED-1 trial Anti-tumor activity was observed in all three evaluable patients with CIS, including one heavily pre-treated BCG-unresponsive patient who achieved a complete response Company...
2023-03-08 09:06:52 ET Protara Therapeutics press release ( NASDAQ: TARA ): Q4 GAAP EPS of -$3.46. Net loss of $39.0 million, compared with a net loss of $10.2 million for the same period in 2021. Net loss in the fourth quarter of 2022 included a non-cash goodwill...
- Data from Phase 1a Portion of ADVANCED-1 Trial of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer Expected in 2Q23 – - Start up Activities for Phase 2 Trial of TARA-002 in Lymphatic Malformations Underway; Trial Initiation Expected 2H23 - - Cash, Cash E...
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare ...
News, Short Squeeze, Breakout and More Instantly...
ArTara Therapeutics Inc. Company Name:
TARA Stock Symbol:
NASDAQ Market:
ArTara Therapeutics Inc. Website:
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grant of inducement non-qualified stock options to purchase an aggregate of 118,40...
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 5t...
Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBC Preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC expected in 2H 2024 Reached alignment with FDA on registrational p...